Would you treat a patients with metastatic squamous cell lung cancer with >/= 50% PDL-1 expression with first line pembrolizumab/carboplatin/paclitaxel combination or with pembrolizumab alone?  

Keynote 407 recently published data on pembrolizumab +/- chemo for metastatic squamous cell lung cancer.  The confidence interval for the group with >/= 50% PDL-1 expression was wide and crossed one.  For this group would you be more inclined to treat with first line pembrolizumab alone?